Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Cancer Biology & Therapy|April 6, 2021
Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinibLily Deland, Simon Keane, Thomas Olsson Bontell, et al.
Cell Death & Disease|December 15, 2017
BET bromodomain inhibitors synergize with ATR inhibitors in melanomaSomsundar Veppil Muralidharan, Berglind Osk Einarsdottir, Joydeep Bhadury, et al.
Plos One|January 3, 2023
SARS-CoV-2 replicates and displays oncolytic properties in clear cell and papillary renal cell carcinomaOi Kuan Choong, Rasmus Jakobsson, Anna Grenabo Bergdahl, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2014
BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphomaJoydeep Bhadury, Lisa M Nilsson, Somsundar Veppil Muralidharan, et al.
Cancer Research|January 10, 2019
HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout MiceElin M V Forsberg, Mattias F Lindberg, Henrik Jespersen, et al.
Blood|August 22, 2014
Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphomaAlexander Hoellein, Mohammad Fallahi, Stephanie Schoeffmann, et al.
Cancer Cell|May 17, 2005
Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formationJonas A Nilsson, Ulrich B Keller, Troy A Baudino, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 8, 2017
BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cellsTaral R Lunavat, Lesley Cheng, Berglind O Einarsdottir, et al.
Cancers|February 11, 2023
Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion DogsElin M V Forsberg, Rebecca Riise, Sara Saellström, et al.
BMC Cancer|May 4, 2019
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label studyHenrik Jespersen, Roger Olofsson Bagge, Gustav Ullenhag, et al.
Pageof 10